Summary
Background
Targeting FVIII expression to platelets is a promising gene therapy approach for hemophilia A and is successful even in the presence of inhibitors. It is well known that platelets not only play important roles in hemostasis, but also in thrombosis and inflammation.
Objective
To evaluate whether platelet-FVIII expression might increase the risk for thrombosis and thereby compromise the safety of this approach.
Methods
In this study, platelet-FVIII expressing transgenic mice were examined either in steady state or under prothrombotic conditions induced by inflammation or the factor V Leiden mutation. Native whole blood thrombin generation assay, ROTEM analysis, and ferric chloride induced vessel injury were used to evaluate the hemostatic properties. Various parameters associated with the thrombosis risk, including D-Dimer, thrombin anti-thrombin complexes, fibrinogen, tissue fibrin deposition, platelet activation status and activatability, and platelet-leukocyte aggregates, were assessed.
Results
We generated a new line of transgenic mice that expressed 30-fold higher platelet-FVIII levels than therapeutically required to restore hemostasis in hemophilic mice. In steady state as well as under prothrombotic conditions induced by LPS-mediated inflammation or the factor V Leiden mutation, supratherapeutic levels of platelet-FVIII did not appear thrombogenic. Furthermore, FVIII-expressing platelets were neither hyper-activated nor hyper-activatable upon agonist activation.
Conclusion
We conclude that in mice, more than 30-fold higher platelet FVIII levels than required for therapeutic efficacy in hemophilia A are not associated with a thrombotic predilection.